{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-23-000003","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.607765+00:00","generated_at":"2026-06-20T00:32:15.766962+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lisata's LSTA201 trial in diabetic kidney disease fails to show consistent kidney function improvement","bullets":["Preliminary unaudited cash, equivalents and marketable securities of ~$69.2M as of Dec 31, 2022.","Phase 1b trial of LSTA201 (CD34+ cell therapy) in 6 DKD patients tolerated but no consistent kidney function improvement.","Company will evaluate data and determine next steps; no further clinical study committed.","Corporate presentation attached as Exhibit 99.1 for investor conference use."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-23-000003","json":"https://secwatch.observer/filing/0000320017-23-000003.json","markdown":"https://secwatch.observer/filing/0000320017-23-000003.md","text":"https://secwatch.observer/filing/0000320017-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000003/0000320017-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000003/clbs-20230206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:32:15.766962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}